Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

被引：0

作者：

Singhal, Seema B. ^{[1
]}

Siegel, David Samuel diCapua ^{[2
]}

Martin, Thomas ^{[3
]}

Vij, Ravi ^{[4
]}

Wang, Michael ^{[5
]}

Jakubowiak, Andrzej J. ^{[6
]}

Lonial, Sagar ^{[7
]}

Kukreti, Vishal ^{[8
]}

Zonder, Jeffrey A. ^{[9
]}

Wong, Alvin F. ^{[10
]}

McCulloch, Leanne ^{[10
]}

Kauffman, Michael ^{[10
]}

Badros, Ashraf Z. ^{[11
]}

Niesvizky, Ruben ^{[12
]}

Orlowski, Robert Z. ^{[13
]}

Stewart, A. Keith ^{[14
]}

Jagannath, Sundar ^{[15
]}

机构：

[1] Northwestern Univ, Feinberg Sch Med, Div Hem Onc, Chicago, IL 60611 USA

[2] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[3] Univ San Francisco, San Francisco, CA 94117 USA

[4] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[5] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[8] Princess Margaret Hosp, Div Hematol Oncol, Toronto, ON M4X 1K9, Canada

[9] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[10] Onyx Pharmaceut, Emeryville, CA USA

[11] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[12] Weill Cornell Med Coll, New York, NY USA

[13] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[14] Mayo Clin Arizona, Scottsdale, AZ USA

[15] Mt Sinai Med Ctr, Multiple Myeloma Program, New York, NY 10029 USA

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：814 / 815

页数：2

共 50 条

[1] Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis
Singhal, Seema
Siegel, David S.
Martin, Thomas
Vij, Ravi
Wang, Luhua
Jakubowiak, Andrzej J.
Lonial, Sagar
Kukreti, Vishal
Zonder, Jeffrey A.
Wong, Alvin F.
McCulloch, Leanne
Badros, Ashraf Z.
Niesvizky, Ruben
Orlowski, Robert Z.
Stewart, A. Keith
Kotlovker, Debbi
Jagannath, Sundar
BLOOD, 2011, 118 (21) : 819 - 819
[2] Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
Jakubowiak, Andrzej
Wang, Luhua
Orlowski, Robert Z.
Jagannath, Sundar
Siegel, David
Stewart, A. Keith
Kukreti, Vishal
Lonial, Sagar
McDonagh, Kevin T.
Vallone, Marcy
Kauffman, Michael
Vij, Ravi
BLOOD, 2009, 114 (22) : 725 - 726
[3] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
Berdeja, Jesus G.
Gregory, Tara K.
Matous, Jeffrey
Hart, Lowell L.
Owera, Rami
Mace, Joseph Ronald
Essell, James H.
Flinn, Ian
Faber, Edward Anthony
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[4] Phase 1 MMRC Trial of Selinexor, Carfilzomib (CFZ), and Dexamethasone (DEX) in Relapsed and Relapsed/Refractory Multiple Myeloma (RRMM)
Jakubowiak, Andrzej
Jasielec, Jagoda
Rosenbaum, Cara A.
Zonder, Jeffrey A.
Cole, Craig E.
Chari, Ajai
Nam, Jennifer
Stephens, Leonor A.
McDonnell, Kathryn
Uribe, Rebecca
Rosebeck, Shaun
Rashal, Tami
Youssoufian, Hagop
Henry, Sarah
Shacham, Sharon
Kauffman, Michael
Zimmerman, Todd
Karrison, Theodore
BLOOD, 2015, 126 (23)
[5] Efficacy and Safety of Carfilzomib-Pomalidomide-Dexamethasone in Relapsed and/or Refractory Multiple Myeloma: Pooled Analysis of 2 Single Arm Studies
Jakubowiak, Andrzej
Jasielec, Jagoda
Rosenbaum, Cara
Orlowski, Robert Z.
Cohen, Adam
Bensinger, William I.
Anderson, Aparna
Dossett, Tommy
Iskander, Karim
Mezzi, Khalid
Welliver, Timothy
Yusuf, Akeem
Durie, Brian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E34 - E34
[6] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
Watanabe, Takashi
Tobinai, Kensei
Matsumoto, Morio
Suzuki, Kenshi
Sunami, Kazutaka
Ishida, Tadao
Ando, Kiyoshi
Chou, Takaaki
Ozaki, Shuji
Taniwaki, Masafumi
Uike, Naokuni
Shibayama, Hirohiko
Hatake, Kiyohiko
Izutsu, Koji
Ishikawa, Takayuki
Shumiya, Yoshihisa
Kashihara, Tomohisa
Iida, Shinsuke
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
[7] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma
Xu, Wenjun
Sun, Xuedong
Wang, Baohong
Guo, Hui
ANNALS OF HEMATOLOGY, 2018, 97 (02) : 299 - 307
[8] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma
Wenjun Xu
Xuedong Sun
Baohong Wang
Hui Guo
Annals of Hematology, 2018, 97 : 299 - 307
[9] Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
Samuel, David
Martin, Thomas
Wang, Michael
Vij, Ravi
Jakubowiak, Andrzej J.
Jagannath, Sundar
Lonial, Sagar
Kukreti, Vishal
Bahlis, Nizar J.
Alsina, Melissa
Chanan-Khan, Asher A.
Somlo, George
Buadi, Francis
Reu, Frederic J.
Zonder, Jeffrey A.
Song, Kevin
Stadtmauer, Edward
Wong, Alvin F.
Vallone, Marcy
Chang, Yu-Lin
Kauffman, Michael
Orlowski, Robert Z.
Stewart, A. Keith
Singhal, Seema B.
BLOOD, 2010, 116 (21) : 433 - 433
[10] Phase I/II Study of Panobinostat and Carfilzomib in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Interim Phase I Safety Analysis
Berdeja, Jesus G.
Hart, Lowell
Lamar, Ruth
Murphy, Patrick
Morgan, Susan
Flinn, Ian W.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →